Trial Profile
A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Belzutifan (Primary)
- Indications Glioblastoma; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Peloton Therapeutics
- 16 Sep 2022 Planned End Date changed from 14 Apr 2023 to 14 Apr 2025.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 13 Feb 2021 Results assessing additional follow-up from the expansion cohort of patients with ccRCC from the first-in-human phase 1/2 study of MK-6482 in advanced solid tumors, presented at the 2021 Genitourinary Cancers Symposium.